View full prescribing information

About ILUVIEN – Designed by Ophthalmologists for Ophthalmologists

Together chemistry and technology enable long-acting, continuous, low dose, steroid release with ILUVIEN for up to 36 months1

1. Habib MS. Ther Deliv 2018;

The ILUVIEN Implant

The external capsule is made from polyimide, an inert material used in the haptics of intra-ocular lenses.

ILUVIEN has a non-permeable plug at one end. At the other end is a permeable membrane made of poly-vinyl alcohol (PVA) that allows the molecular passage of fluocinolone acetonide.

The internal part of the implant consists of a PVA matrix + fluocinolone acetonide molecules.

CONTINUOUS MICRODOSING Technology

ILUVIEN CONTINUOUS MICRODOSING results in zero order kinetics with stable steroid release for up to 3 years. Whilst most drugs are eliminated via first-order kinetics2, elimination with ILUVIEN is time rather than concentration dependent from approximately 6 months after administration1

Aqueous levels of Fluocinolone acetonide in human eyes1

FAc = Flucocinolone acetonide

Data presented as mean ± standard error

1. ILUVIEN, Summary of Product Characteristics.
2. Campochiaro PA, Brown DM, et al. Ophthalmology 2011; 118: 626-635.

Unique Delivery System

ILUVIEN’s applicator has a 25 gauge needle, which produces a self-sealing wound, with no need for a tunnelling procedure. The injection is simple and is performed at 4 mm inferotemporal from the limbus. As there is no spring in the device, the implant is “smoothly” delivered into the posterior part of the eye, where it settles in the vitreous and starts releasing the fluocinolone acetonide (FAc).